As part of the demand for dismissal, MIT provides stipulated it will be bound by any declaratory, injunctive, or equitable alleviation to the degree that the Courtroom may ultimately award such relief against the Whitehead Institute for Biomedical Analysis or the University of Massachusetts. UMass and Whitehead stay as defendants in the suit, in June 2009 that was originally filed. As this matter can be in active litigation, Alnylam and Max Planck will not be in a position to provide specific details in response to inquiries on this topic.. Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation Alnylam Pharmaceuticals, Inc.Thus, Sanofi Pasteur can be continuing its clinical development program for this brand-new vaccine which we believe will offer you public health advantages. announced today that it finished an End-of-Review ending up in the U.S. Meals and Medication Administration for the AZ-004 New Drug Software , and has received the official FDA minutes from the meeting. ‘We enjoy the FDA’s overview of the initial NDA for our novel Staccato technology and we will work to address problems raised in the Complete Response Letter,’ said Thomas B. King, Alexza President and CEO.’ As reported in October 2010, the FDA stated in the CRL that their main clinical safety concern was linked to data from the three Stage 1 pulmonary safety studies with AZ-004. Related StoriesMayo Clinic research analyzes asthma outcomes after sufferers step down daily medicinesResearchers find protein that plays crucial function in development of allergic airway inflammationResearchers evaluate effectiveness of combination therapy for black sufferers with asthmaIn the info package, Alexza also showed that the pulmonary security program in subjects with asthma and COPD experienced identified sufferers who may be susceptible to bronchospasm, the nature of this event, how it can be maintained, and that Alexza believed the risk in these patients could be mitigated through labeling and a Risk Evaluation and Mitigation Technique system.